Ablacare
AblaCare rebranded as May Health in September 2022 and now operates at mayhealth.com; ablacare.com 301-redirects there. It is a clinical-stage medical device company headquartered in Paris, France, founded in 2017 out of Sofinnova Partners' MD Start medtech acceleration program. The company develops Ovarian Rebalancing, a one-time minimally invasive in-office procedure using ultrasound-guided radiofrequency ablation of ovarian tissue to restore spontaneous ovulation in women with infertility related to polycystic ovary syndrome (PCOS). It raised a EUR 10M Series A in 2019, a USD 25M Series B co-led by Bpifrance and Trill Impact Ventures in 2024, and is running the randomized REBALANCE pivotal study intended to support an FDA submission. It publishes no developer program, API or SDK.
Ablacare is profiled on the APIs.io network. Tagged areas include Health Care, Medical Devices, Femtech, Fertility, and Womens Health.
Ablacare’s developer surface includes support and 5 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 2
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.